Buy & Sell AbbVie Inc (ABBV) – AbbVie Inc Price Today
Aura AI Summary
Key Stats
- $447.62BMarket Cap
- HealthSector
- -9.23%3M Drawdown
- $511.08BEnterprise Value
- 2.73%Dividend Yield
- 90 daysTypical Hold Time
AbbVie Inc (ABBV) is currently valued at a market capitalization of $447.62B, with an enterprise value of $511.08B. Over the past 52 weeks, AbbVie Inc has traded between a low of $182.31 and a high of $254.25, highlighting its annual price range. Over the past three months, AbbVie Inc has recorded a drawdown of -9.23%, reflecting recent price volatility. AbbVie Inc offers a dividend yield of 2.73%, with the most recent dividend of $1.73 paid on 15 Apr 26. On average, investors hold AbbVie Inc for approximately 90 days, indicating typical investor behavior on the platform.
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Most Recent News
State Street Global Advisors reduces stake in DCC plc below 1.4% with recent share sales.
State Street Global Advisors & Affiliates disclosed a reduction in their holdings of DCC plc ordinary shares to 1,193,218 shares, representing 1.39682% of the company. The reduction involved selling 1,544 shares at €62.30 each on June 26, 2026. This ...

Global head-up display market to nearly double to $13.7B by 2030, driven by digital cockpits and EV growth.
The global head-up display (HUD) market is expected to grow from $6.9 billion in 2024 to $13.7 billion by 2030, at a CAGR of 12.8%, fueled by rising demand for digital cockpits and advanced driver assistance systems in vehicles. Asia-Pacific leads wi...

Study shows 1 in 7 patients switch back to Humira after moving to biosimilars post-formulary changes
A new study analyzing nearly 68,000 US patients found that adoption of adalimumab biosimilars increased significantly after formulary changes, but over 16% of those who switched from Humira reverted back to the original drug. The research highlights ...
